Project Grant R21AI178534

Award Date 6/1/24
Completion Date 5/31/26
Dollars Obligated $683K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bryan, TX 77807, USA
Similar Awards
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This $450,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the role of different lung macrophage subsets in the maintenance of tuberculosis (TB) lesions and the local environment of Mycobacterium tuberculosis (MTB) infection. The research team at the University of Arkansas for Medical Sciences will utilize novel metabolic analysis and spatial...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,503,349 to the University of Arkansas for Medical Sciences (UAMS) to study the ontogeny (origin) and metabolism of lung alveolar macrophages and their role in tuberculosis (TB) infection. The overarching goal is to understand how the origin and metabolic pathways of these immune cells impact their...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This Project Grant award of $451,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to develop a human lung alveolus-on-a-chip model for studying non-tuberculous mycobacteria (NTM) infections. The goal is to gain insights into NTM pathogenesis, host-pathogen interactions, and identify potential...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and...
This federal Project Grant award of $489,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the establishment of a novel human lung alveolar epithelial cell organoid model to study Mycobacterium tuberculosis (MTB) infection and host innate immune responses. The primary objectives are to develop a physiologically relevant in vitro platform using human bronchoalveolar lavage fluid (BALF) to...

ELUCIDATION OF THE MOLECULAR MECHANISM(S) FOR THE NON-RESPONSIVENESS OF CD38- AMS TO TUBERCULOSIS INFECTION - THE LUNG-RESIDENT ALVEOLAR MACROPHAGES (AMS) ARE THE INITIAL HOST CELLS INFECTED BY INHALED MYCOBACTERIUM TUBERCULOSIS (MTB). WHILE TRADITIONALLY PERCEIVED AS A CONDUCIVE ENVIRONMENT FOR MTB REPLICATION AND SPREAD, OUR RECENT STUDIES USING FLUORESCENT MTB FITNESS REPORTER STRAINS AND SINGLE-CELL RNA-SEQUENCING (SCRNA-SEQ) HAVE REVEALED A MORE INTRICATE REALITY. WE DISCOVERED TWO PRIMARY AM POPULATIONS IN THE MTB-INFECTED LUNG: SIGLECF+ CD38+ PRO-INFLAMMATORY AMS, WHICH HOUSE STRESSED BACTERIA AND EXPRESS HIGH LEVELS OF NOS2, AND SIGLECF+ CD38- AMS, WHICH LACK NOS2 EXPRESSION AND ACCOMMODATE REPLICATIVE BACTERIA. INTRIGUINGLY, OUR PRELIMINARY FINDINGS INDICATE THAT CD38- AMS, WHICH EXHIBIT LIMITED MTB CONTAINMENT CAPABILITIES, ARE THE PREDOMINANT INFECTED AM POPULATION DURING THE EARLY INFECTION STAGES. MOREOVER, INTRANASAL BCG VACCINATION PRIOR TO MTB EXPOSURE SIGNIFICANTLY REDUCES THE NUMBER OF MTB-INFECTED HOST CELLS AND MARKEDLY INCREASES THE PROPORTION OF CD38+ INFECTED AMS. THIS SUGGESTS A CRITICAL ROLE FOR THE CD38+ AM PHENOTYPE IN TRIGGERING A PROTECTIVE IMMUNE RESPONSE FOLLOWING VACCINATION. ALTHOUGH THESE AM SUBSETS APPEAR TRANSCRIPTIONALLY INDISTINGUISHABLE IN NAIVE MICE, THEY DEMONSTRATE DISTINCT CHROMATIN ORGANIZATION, SUGGESTING THAT EPIGENETIC FACTORS DICTATE THEIR RESPONSE TO INFECTION. OUR HYPOTHESIS IS THAT A HIGHER PREVALENCE OF CD38+ AMS WITHIN THE LUNG AIRWAYS LEADS TO IMPROVED EARLY INHIBITION OF MTB PROLIFERATION AND SPREAD, THEREBY UNVEILING A VIABLE AVENUE FOR IMMUNE MEDIATE CONTROL OF TUBERCULOSIS INFECTION. SPECIFIC AIM 1: ELUCIDATE THE HOST MOLECULAR MECHANISMS CONTRIBUTING TO THE LIMITED RESPONSE OF CD38- AMS TO MTB INFECTION. TO DECIPHER THE HOST MOLECULAR MECHANISMS UNDERLYING THE BLUNTED RESPONSE OF CD38- AMS TO MTB INFECTION, WE WILL EMPLOY AN INTEGRATED MULTI-OMICS APPROACH TO ANALYZE THE CHANGES IN CHROMATIN ORGANIZATION AND TRANSCRIPTION FACTOR ACTIVITY POST-MTB INFECTION. WE WILL THEN MANIPULATE THE AM IMMUNE ENVIRONMENT THROUGH INTRANASAL BCG VACCINATION TO IDENTIFY THOSE EPIGENETIC CHANGES THAT ARE ASSOCIATED WITH LONG-TERM PROTECTION AGAINST MTB INFECTION. SPECIFIC AIM 2: IMPLEMENT CRISPR-BASED GENETIC PERTURBATION APPROACHES IN MACROPHAGES TO EVALUATE THE ROLE OF SELECTED HOST RESPONSES IN MTB INFECTION. INITIALLY, WE WILL USE A CRISPR-BASED GENETIC PERTURBATION APPROACH TO VALIDATE THE ROLE OF CANDIDATE HOST GENES, IDENTIFIED IN OUR EXISTING DATASETS, IN GENERATING PRO-INFLAMMATORY MACROPHAGE RESPONSES THAT CONTROL MTB INFECTION. WE WILL THEN EXTEND THIS APPROACH TO FUNCTIONALLY VALIDATE ADDITIONAL TARGETS EMERGING FROM SPECIFIC AIM 1.

Posted 5/31/24